A low ratio of n-6/n-3 polyunsaturated fatty acids suppresses matrix metalloproteinase 13 expression and reduces adjuvant-induced arthritis in rats

Nutr Res. 2015 Dec;35(12):1113-21. doi: 10.1016/j.nutres.2015.09.019.

Abstract

Increased expression of matrix metalloproteinase 13 (MMP13) in chondrocytes contributes to the development of osteoarthritis. The hypothesis of this study was that diet with a low ratio of n-6/n-3 polyunsaturated fatty acids (PUFAs) is associated with reduced MMP13 expression in inflammatory chondrocytes in vitro and in vivo. Human chondrocytes were cultured with different ratios of linoleic acid (LA, n-6 PUFA) to α-linolenic acid (n-3 PUFA) from 1:1 to 10:1. Proliferation of chondrocytes, MMP13 protein and mRNA levels were detected, respectively. Sprague-Dawley rats (n=30) were fed diets containing different ratios of n-6/n-3 PUFA. Freund's complete adjuvant was injected to make the model of arthritis. Paw swelling rate was measured and all rats were euthanized after 6 weeks of treatment. Serum MMP13 and IL-1 were measured by enzyme-linked immunosorbent assay. Joint histological sections were stained with safranin-O Fast Green to evaluate cartilage damage. Low ratio of LA/α-linolenic acid decreased the mRNA and protein levels of MMP13 but did not affect chondrocytes proliferation. Ratios of PUFA such as 1:1 and 2:1 significantly reduced paw swelling rate, and serum MMP13 and IL-1 levels in a rat model. Histological staining showed that ratios of 1:1 and 2:1 PUFA significantly alleviated cartilage damage in adjuvant-induced arthritis. A ratio of n-6/n-3 PUFA of 1:1 showed the strongest inhibitory effect on MMP13. Our results indicate that a low ratio of n-6/n-3 PUFA at 1:1 significantly suppressed MMP13 expression both in vitro and in vivo and reduced adjuvant-induced arthritis in rats could be a means to control and reduce the symptoms of osteoarthritis.

Keywords: Chondrocytes; Fatty acids; Matrix metalloproteinase 13; Osteoarthritis; Rat; Ratio of PUFA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arthritis, Experimental / blood
  • Arthritis, Experimental / diet therapy*
  • Arthritis, Experimental / genetics
  • Arthritis, Experimental / pathology
  • Cartilage / drug effects*
  • Cartilage / pathology
  • Cartilage Diseases / blood
  • Cartilage Diseases / diet therapy
  • Cartilage Diseases / genetics
  • Cartilage Diseases / pathology
  • Chondrocytes / drug effects
  • Edema
  • Humans
  • Interleukin-1 / blood
  • Joints / drug effects*
  • Joints / pathology
  • Linoleic Acid / administration & dosage
  • Linoleic Acid / pharmacology*
  • Male
  • Matrix Metalloproteinase 13 / blood*
  • Matrix Metalloproteinase 13 / genetics
  • Osteoarthritis / blood
  • Osteoarthritis / diet therapy*
  • Osteoarthritis / genetics
  • Osteoarthritis / pathology
  • RNA, Messenger / metabolism
  • Rats, Sprague-Dawley
  • alpha-Linolenic Acid / administration & dosage
  • alpha-Linolenic Acid / pharmacology*

Substances

  • Interleukin-1
  • RNA, Messenger
  • alpha-Linolenic Acid
  • Linoleic Acid
  • Matrix Metalloproteinase 13